Overexpression of the potential kinase serine/threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer

Cancer Science

Volumn 100, Issue 11, 2009, Pages 2109-2114

  Chung, Suyoun ^a   Tamura, Kenji ^b   Furihata, Mutsuo ^b   Uemura, Motohide ^a   Daigo, Yataro ^a   Nasu, Yasutomo ^c   Miki, Tsuneharu ^d   Shuin, Taro ^b   Fujioka, Tomoaki ^e   Nakamura, Yusuke ^a   Nakagawa, Hidewaki ^a,f  

^a UNIVERSITY OF TOKYO   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e IWATE MEDICAL UNIVERSITY   (Japan)

^f RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE; PROTEIN KINASE STYK 1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CASTRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; RNA ANALYSIS; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR SEQUENCE DATA; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 71049181019     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01277.x     Document Type: Article

References (27)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003, 361:859-64.
2. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001, 166:416-19.
3. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clinic Proc 2001, 76:576-81.
4. Roberts WW, Bergstralh EJ, Blute ML. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001, 57:1033-7.
5. Grossmann ME, Huang HJ, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001, 93:1687-97.
6. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999, 5:280-5.
7. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003, 112:1724-31.
8. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001, 1:34-45.
9. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23:8253-61.
10. Signoretti S, Montironi R, Manola J. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000, 92:1918-25.
11. Osman I, Scher HI, Drobnjak M. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001, 7:2643-7.
12. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-34.
13. Davies H, Hunter C, Smith R. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005, 65:7591-5.
14. Zhang JM, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
15. Tamura K, Furihata M, Tsunoda T. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007, 67:5117-25.
16. Ye X, Ji CN, Huang QS. Isolation and characterization of a human putative receptor protein kinase cDNA STYK1. Mol Biol Rep 2003, 30:91-6.
17. Liu L, Yu XZ, Li TS. A novel protein tyrosine kinase NOK that shares homology with platelet-derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res 2004, 64:3491-9.
18. Kimbro KS, Duschene K, Willard M, Moore JA, Freeman S. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Mol Biol Rep 2008, 35:23-7.
19. Amachika T, Kobayashi D, Moriai R, Tsuji N, Watanabe N. Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer 2007, 56:337-40.
20. Ashida S, Nakagawa H, Katagiri T. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 2004, 64:5963-72.
21. Anazawa Y, Nakagawa H, Furihara M. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. Cancer Res 2005, 65:4578-86.
22. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. Trends Cell Biol 2006, 16:443-52.
23. Tannock IF, de Wit R, Berry WR. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004, 351:1502-12.
24. Petrylak DP, Tangen CM, Hussain MHA. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 2004, 351:1513-20.
25. Katso RM, Russell RB, Ganesan TS. Functional analysis of H-Ryk, an atypical member of the receptor tyrosine kinase family. Mol Cell Biol 1999, 19:6427-40.
26. Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 2009, 17:128-38.
27. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003, 2:296-313.